

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5653382

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY	03/01/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SHINE BIOPHARMA, INC.
<b>Street Address:</b>	5F, 14, CHEONGGYECHEON-RO, JUNG-GU
<b>City:</b>	SEOUL
<b>State/Country:</b>	KOREA, REPUBLIC OF
<b>Postal Code:</b>	04520
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15897138
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)938-5200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	6503357908
<b>Email:</b>	kwoo@fenwick.com
<b>Correspondent Name:</b>	HAYAN YOON
<b>Address Line 1:</b>	FENWICK & WEST LLP
<b>Address Line 2:</b>	801 CALIFORNIA STREET
<b>Address Line 4:</b>	MOUNTAIN VIEW, CALIFORNIA 94041
<b>ATTORNEY DOCKET NUMBER:</b>	34688-39923/US (001US)
<b>NAME OF SUBMITTER:</b>	HAYAN YOON, REG NO. L0954
<b>SIGNATURE:</b>	/Hayan Yoon/
<b>DATE SIGNED:</b>	08/05/2019
<b>Total Attachments: 3</b>	
source=Yonsei to Shine#page1.tif	
source=Yonsei to Shine#page2.tif	
source=Yonsei to Shine#page3.tif	

## CONFIRMATORY ASSIGNMENT

THIS CONFIRMATORY ASSIGNMENT is made by and between **INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY**, 50 Yonsei-ro, Seodaeun-gu, Seoul 03722, Korea ("ASSIGNOR") and **SHINE BIOPHARMA, INC.**, a corporation of the Republic of Korea, having a place of business at 5F, 14, Cheonggyecheon-ro, Jung-gu, Seoul 04520, Republic of Korea ("ASSIGNEE").

WHEREAS, pursuant to an agreement made on November 22, 2016 (the "2016 Agreement") between Kang-Yell CHOI and Mi-Yeon KIM (collectively, "INVENTOR") and ASSIGNOR, and subsequently confirmed by confirmatory assignments recorded in the US Patent & Trademark Office respectively at reel/frame 049935/0710 and 049937/0198, ASSIGNOR did acquire from INVENTOR,

with full title guarantee, free from all and any charges or other third party rights, absolutely all of entire worldwide right, title, and interest in and to all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following patent application:

- Korean Application No. 10-2016-0158739, entitled "COMPOSITION FOR PROLIFERATION AND DIFFERENTIATION OF MULTI-POTENT NEURAL STEM CELL AND METHOD FOR INDUCING DIFFERENTIATION USING THE SAME", filed 25 November 2016 (hereinafter, referred to as the "APPLICATION");

and the entire worldwide right, title, and interest in and to: (a) the APPLICATION; (b) the right to claim priority to the APPLICATION; (c) the right to file patent applications directly in the name of the ASSIGNOR (in countries or regions where such filings are permissible); (d) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto that have been or may be filed in the United States or elsewhere in the world; and (e) all patents (including reissues and re-examinations) that may be granted on the applications set forth in (a), (b), (c) and (d) above (collectively, the APPLICATION RIGHTS);

WHEREAS, pursuant to an agreement made as of February 1, 2017, between ASSIGNOR and ASSIGNEE, ASSIGNOR agreed to assign and did assign to ASSIGNEE the entire right, title and interest acquired from INVENTOR pursuant to the 2016 Agreement;

WHEREAS, ASSIGNEE desires to confirm that it has acquired the entire right, title and interest in and to the SUBJECT MATTER, and in and to all embodiments of the SUBJECT MATTER heretofore conceived, made or discovered by INVENTOR or jointly by INVENTOR, and in and to the APPLICATION RIGHTS;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby confirms that it has sold, assigned, and transferred and does hereby sell, assign, and transfer to ASSIGNEE, the following:

1. The entire worldwide right, title, and interest in and to the SUBJECT MATTER;
2. The entire worldwide right, title, and interest in and to the APPLICATION RIGHTS, including but not limited to:
  - \* International Application No. PCT/KR2017/013444, entitled "COMPOSITION FOR PROMOTING DIFFERENTIATION OF AND PROTECTING NEURAL STEM CELLS AND METHOD FOR INDUCING NEURAL REGENERATION USING SAME", filed on November 23, 2017, which claims priority from Korean Application No. 10-2016-0158739, filed November 25, 2016 and Korean Application No. 10-2017-0036268, filed March 22, 2017; and
  - \* U.S. Application No. 15/897,138, filed on February 14, 2018, which claims priority from International Application No. PCT/KR2017/013444.

ASSIGNOR confirms that it agreed and does hereby agree that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

ASSIGNOR confirms that it agreed and does hereby agree to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR had the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the ASSIGNOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

ASSIGNOR confirms that it grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or other authority for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Duly Authorized Representative of ASSIGNOR

Date of Signature

  
[signature]

MARCH 1, 2019

LEE, WON-YONG

Name

President

Title

INDUSTRY-ACADEMIC COOPERATION FOUNDATION  
YONSEI UNIVERSITY

Duly Authorized Representative of ASSIGNEE

Date of Signature

  
[signature]

March 1<sup>st</sup>, 2019

Sangho Han

Name

CEO

Title

SHINE BIOPHARMA, INC.